This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Updates Pharmacology : Olaf van Tellingen group

Vacancy PhD Student

Preclinical Pharmacokinetics - Pharmacodynamics of small molecule drugs for treatment of cancer.

Your function within the department

One of the research aims of the research group of Olaf van Tellingen at the Division of Pharmacology is to improve the predictive value of preclinical murine models of cancer. Although the work in his team is centered around brain tumors, the scope of this project will also be on other tumor types. Mouse models of cancer are central in the development of anticancer therapy. Unfortunately, promising results observed in preclinical models often fail to translate to clinical benefit in patients. Although there likely are several factors that contribute to this lack of predictivity, one often neglected aspect is the pharmacological translation from experimental species to patients. In this project, you will investigate the pharmacokinetic - pharmacodynamic (PK-PD) relationship of anticancer drugs and their respective targets in preclinical models. You will focus on the differences in drug exposure between rodents and humans and drug distribution between ectopic and orthotopic tumor models. The ultimate aim of the project is to demonstrate how taking the pharmacological translation into consideration can improve the predictive value of preclinical cancer models.

Your profile

We are seeking an ambitious, highly motivated PhD student with a strong commitment to science and a keen interest to work at the intersection of Pharmacology and Medical biology. You are attracted to interact in a strong team, but capable to work independently. This work will involve analytical (LC-MS/MS) and biological assays, in vitro (cell culture) and in vivo (mouse/rat) models. An MSc in Pharmacology or Oncology and experience with any of these techniques is advantageous. The possession of or commitment to acquire an animal license (Art. 9) is mandatory.

You will join a dynamic international research division and collaborate with scientists and clinicians within and outside the NKI-AVL with expertise in different disciplines. Graduate students at the NKI participate in the education program of the Oncology Graduate School (OOA) Amsterdam. Supervision and promotion of career will be carried out by experts in their respective fields.

Your career opportunities and terms of employment

Your temporary employment is for a period of 4 years with a possible extension of another year. The gross salary per month will be from € 2,798 to € 3,446, according to the standard PhD scales. The terms of employment will be in accordance with the CAO Ziekenhuizen (Collective Labour Agreement for Hospitals) and can be consulted at http://www.nvz-ziekenhuizen.nl/cao-kenniscentrum/cao/download

Amsterdam is a very lively city with many cultural amenities. The institute is located within a 20 minute tram or bicycle ride from the city center and within 20 minutes from Schiphol airport by car, bus or bicycle.

Interested?

For further information about the position, please contact. dr. Olaf van Tellingen, Division of Pharmacology (tel. +31 20 512 2792, e-mail o.v.tellingen@nki.nl). To apply for the position, please follow the link below.

Van Tellingen LiggendOlaf van TellingenGroup leader

Apply for the position

Pint of Science Festival

The Pint of Science festival aims to deliver interesting, fun, relevant talks on the latest science research in an accessible format to the public - all in the pub! During the upcoming edition on May 20th, Paul Slangen, Mark de Gooijer and Inge Verbrugge will be hosting an evening themed 'The Brain: can we beat this obstacle course?'.

The event is freely admissible, but registration is required and can be done by following the link below. We hope to see you all there!

 

The Brain: can we beat this obstacle course?

Thesis Mark de Gooijer

On Wednesday January 23rd, 2019, Mark de Gooijer defended his thesis in Pharmaceutical Sciences at the University of Utrecht and was honoured with a cum laude distinction. He was also awarded a silver UIPS medal.

Mounting an attack on the glioblastoma triad: proliferation, invasion and resistance.

Malignant brain tumors respond very poorly to treatment because of uncontrolled cell proliferation, strong invasiveness and resistance to therapy. PhD researcher Mark de Gooijer has shown that, although new treatments can efficiently attack each of these problems separately, combining them will be necessary to provide better prognoses for patients with brain tumors.

https://www.uu.nl/en/background/mounting-an-attack-on-glioblastoma

https://stophersentumoren.nl/Archief2019/mark-de-gooijer-verdedigde-met-succes-zijn-hersentumorproefschrift

https://medidact.com/oncologie/het-opzetten-van-een-gelijktijdige-aanval-op-de-glioblastoomtriade/

De Gooijer, MarkMark de GooijerPostdoc

Grant Stichting Stophersentumoren

We have received a research grant from the Stichting Stophersentumoren, which is being used to for a preclinical proof-of-concept study to assess whether we can improve the therapy of glioblastoma by inhibition of glioma invasion.

Grant Stichting Aniek Hendriksz Second to None

We have received a grant of Stichting Aniek Hendriksz Second to None, which is being used to design and test the use of therapies with clever combinations of targeted agents.

Back to group page

Contact

  • Office manager

    Lara Spee

  • Telephone Number

    +31 20 512 2035

Share this page